Explore perspective articles based on recent FDA approvals and authored by industry professionals, offering practical guidance and inspiration for your future R&D endeavors.
The FDA's list of recent drug approvals offer a powerful lens through which to examine current pharmaceutical and biotech strategies. Staying up to date with the latest FDA approvals provides scientists with valuable insights into effective drug development and process optimization.
To support industrial biotech researchers in their application of these insights, we recommend two highly read Perspective articles from leading pharmaceutical and biotech companies. These articles summarize key takeaways from recent FDA approvals and offer practical guidance, potentially inspiring new ideas for your projects.
Synthetic Approaches to the New Drugs Approved during 2023
Scott P. France, Erick A. Lindsey, Emma L. McInturff*, Simon Berritt, Jacob DeForest, Andrew C. Flick, Sarah Fink, Tony S. Gibson, Kaitlyn Gray, Aran K. Hubbell, Amber M. Johnson, Yiyang Liu, Subham Mahapatra, Rebecca B. Watson, and Zhiyao Zhou
DOI: 10.1021/acs.jmedchem.4c02079
DOI: 10.1021/acs.jmedchem.4c02079
A Medicinal Chemistry Perspective on FDA-Approved Small Molecule Drugs with a Covalent Mechanism of Action
Samuel E. Dalton*, Ornella Di Pietro, and Elisabeth Hennessy
DOI: 10.1021/acs.jmedchem.4c02661
DOI: 10.1021/acs.jmedchem.4c02661
Want More Articles Like These?
ACS Industry Insider is a monthly newsletter designed to help industrial scientists stay on top of the latest innovations in their fields. With just a few clicks, you can choose up to six research areas and receive five curated journal articles per industry each month. This tailored content is accessible only through ACS Industry Insider, granting you full-text access to each article regardless of your institution's subscription status.
Don't miss the opportunity to stay ahead of the curve and explore the latest discoveries driving the future of your field. View a sample ACS Industry Insider for Biotech & Pharma—and sign up today to be part of our insider community!